Abstract:Modifying HIV-1’s envelope glycoprotein glycans can impact its neutralization sensitivity. The use of the knock out cell line GnT1-prevents the elaboration of complex-type glycans, and opens up the glycan shield, increasing bNAb vulnerability. Some bNAb precursors can bind to GnT1-trimers, supporting their use in vaccine priming. However, GnT1-trimers express poorly and exhibit very low infectious counts. Here, we describe two other potentially vaccine-relevant glycoengineered trimers, 1) To truncate complex glycans, we used of a cocktail of glycosidases, termed “NGAF3” ( euraminidase, β- alactosidase, N- cetylglucosaminidase and endoglycosidase ). Like GnT1-trimers, NGAF3 reduced glycan clashes and increased bNAb potency while retaining a closed trimer conformation; 2) Modified by β-1,4-galactosyltransferase 1 (B4GalT1) and β-galactoside α-2,6 sialyltransferase 1 (ST6Gal1) during Env biosynthesis. Glycan mass spectrometry revealed that NGAF3 removed glycan heads of 3 of 7 positions on the trimer that are largely occupied by complex glycans. It also revealed a novel B4GalT1 activity to favor glycan precursor conversion to hybrid glycans rather than complex glycans. A comparison to monomeric gp120 revealed that B4GalT1’s new activity depends on tight glycan spacing. B4GalT1 affected more glycans than NGAF3 (6 out of 7 glycans), perhaps due to greater accessibility Env folding rather than folding. Surprisingly, the N611 glycan was unaffected by either modification. B4GalT1 and ST6Gal1 cooperatively increased the abundance of hybrid glycans and α-2,6 hypersialylated termini. This occurred largely by amplifying the abundance of a limited number of hybrid glycan structures that are also present on unmodified trimers. In rabbit vaccinations, B4GalT1+ST6GalT1-modified virus-like particles reduced the frequency and titers of serum NAbs that showed a modest preference for modified glycans. Conversely, chronically HIV-1-infected donor plasma neutralizing antibody titers were 1.7- to 10.8- fold higher against B4GalT1+ST6GalT1-modified pseudovirus. Overall, our data provide tools for heterologous prime, boost and polishing vaccine regimens using modified glycans.

Deglycosylation of Hiv-1 Ae Gp140 Enhances the Capacity to Elicit Neutralizing Antibodies Against the Heterologous Hiv-1 Clade

Envelope Deglycosylation Enhances Antigenicity of HIV-1 Gp41 Epitopes for Both Broad Neutralizing Antibodies and Their Unmutated Ancestor Antibodies

Modified HIV Envelope Proteins with Enhanced Binding to Neutralizing Monoclonal Antibodies

Influence of HIV-1CN54 Gp145 deglycosylation on its immunogenicity

Improving immunogenicity of HIV-1 envelope gp120 by glycan removal and immune complex formation.

Broad HIV-1 Neutralizing Antibody Response Induced by Heterologous Gp140/gp145 DNA Prime-Vaccinia Boost Immunization

HIV-1 envelope glycan modifications that permit neutralization by germline-reverted VRC01-class broadly neutralizing antibodies

Impact of Glycan Depletion, Glycan Debranching and Increased Glycan Charge on HIV-1 Neutralization Sensitivity and Immunogenicity

Short Communication: in VitroSynergy Between Peptides or Neutralizing Antibodies Targeting the N- and C-Terminal Heptad Repeats of HIV Type 1 Gp41

Amino Acid Changes in the HIV-1 Gp41 Membrane Proximal Region Control Virus Neutralization Sensitivity

Recognition Of Synthetic Glycopeptides By Hiv-1 Broadly Neutralizing Antibodies And Their Unmutated Ancestors

Broader HIV-1 Neutralizing Antibody Responses Induced by Envelope Glycoprotein Mutants Based on the EIAV Attenuated Vaccine

Comparison of Antibody Immune responses to different HIV-1 Envelope Glycoprotein Mutants.

Immunogenicity of virus-like particles containing modified human immunodeficiency virus envelope proteins.

Neutralization Sensitivity and Evolution of Virus in a Chronic HIV-1 Clade B Infected Patient with Neutralizing Activity Against Membrane-Proximal External Region

Exploration of a Sequential Gp140-Gp145 Immunization Regimen with Heterologous Envs to Induce a Protective Cross-Reactive HIV Neutralizing Antibody Response In Non-human Primates

Altering the Specificity of the Antibody Response to HIV Gp120 with a Glycoconjugate Antigen.

Glycan Masking Focuses Immune Responses to the HIV-1 CD4-Binding Site and Enhances Elicitation of VRC01-Class Precursor Antibodies.

Amino acid substitution of the membrane-proximal external region alter neutralization sensitivity in a chronic HIV-1 clade B infected patient

Comparison of immunogenicity between codon optimized HIV-1 Thailand subtype B gp140 and gp145 vaccines.

Cross-Reactive Human Igm-Derived Monoclonal Antibodies That Bind to Hiv-1 Envelope Glycoproteins